Bioactive Adrenomedullin in Dogs with Sepsis and Septic Shock: A Prospective, Case-Control Study

Eirini Chrysovergi; Carmel T. Mooney; Robert E. Shiel; Evangelia M. Stavroulaki; Kevin Murtagh

Bioactive Adrenomedullin in Dogs with Sepsis and Septic Shock: A Prospective, Case-Control Study

2024

Eirini Chrysovergi | Carmel T. Mooney | Robert E. Shiel | Evangelia M. Stavroulaki | Kevin Murtagh

Sepsis and septic shock are leading causes of morbidity and mortality in both humans and dogs, and early diagnosis is crucial for improving outcomes. This study aimed to evaluate bioactive adrenomedullin (bio-ADM) concentrations in dogs with septic shock (n = 25), dogs with sepsis without evidence of shock (n = 25), and healthy control dogs (n = 25). Plasma bio-ADM concentrations were measured using a human sandwich enzyme-linked immunosorbent assay and reported as median (interquartile range). Plasma bio-ADM concentrations were significantly higher in both septic groups compared to the healthy controls (all <22.4 pg/mL), but not significantly different between the septic shock (75.0 [28.7–115.0] pg/mL) and sepsis (30.7 [22.4–79.7] pg/mL) groups. Dogs with higher illness severity scores had significantly higher bio-ADM concentrations (93.1 [32.2–122.0] pg/mL) than those with lower scores (29.8 [22.4–71.2] pg/mL). However, bio-ADM concentrations did not differ between survivors (33.0 [22.7–76.7] pg/mL) and non-survivors (74.7 [26.1–123.2] pg/mL). Measurement of bio-ADM is a potential marker for canine sepsis, but not for the identification of septic shock, and may provide information on disease severity. Further studies, including those on non-infectious inflammatory conditions, are necessary to better understand the diagnostic utility of bio-ADM measurement and its potential role as a marker of treatment response in dogs with sepsis.

Afficher plus [+]